Journal article
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Abstract
OBJECTIVES: Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial.
METHODS: Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were prospectively enrolled and received remission-induction therapy with rituximab (4×375 mg/m2) and a …
Authors
Smith RM; Jones RB; Specks U; Bond S; Nodale M; Aljayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S
Journal
Annals of the Rheumatic Diseases, Vol. 79, No. 9, pp. 1243–1249
Publisher
Elsevier
Publication Date
September 2020
DOI
10.1136/annrheumdis-2019-216863
ISSN
0003-4967